DNA vaccine

(redirected from DNA vaccination)
Also found in: Medical, Wikipedia.

DNA vaccine

[¦de¦en¦ā vak′sēn]
(immunology)
A type of noninfectious vaccine that directly injects deoxyribonucleic plasmids that express antigens of interest, resulting in foreign protein expression within the cells of the vaccine; however, the vaccine itself is unable to replicate.
Mentioned in ?
References in periodicals archive ?
Using these concepts, we propose to extend this principle to Schmallenberg virus, in order to: i) develop an easy-to-use diagnostic test for Schmallenberg detection; and ii) develop a DNA vaccination strategy that could be used to limit further future outbreaks.
Scientists in a wide range of biomedical disciplines survey the status of new plasmids that have emerged in the development of non-viral vectors for gene and cell therapy and DNA vaccination.
These new results validate the whole potential for the use of this new nanovector in DNA vaccination.
In addition regulatory agencies recognize that the open circular and linear forms of pDNA, are less effective for DNA vaccination than the supercoiled form [13].
We are excited about the promise of this treatment strategy as the DNA vaccination strategy has the potential to be applied in clinical settings in combination with other available therapeutic options.
Others consider antibiotic resistance and its detrimental impact on fish genetics, DNA vaccination and associated immunological reactions, bioconversion of lignocellulosic wastes, transgenic fish, and ethical, legal, and risk assessment issues relating to genetic engineering.
While research to date has found DNA vaccines to be a safe option, the long-term safety associated with DNA vaccination remains to be seen.
The researchers used a technique called DNA vaccination, which introduces a gene into the body to elicit an immune response.
DNA vaccination against ticks: DNA vaccine development is still in its infancy for ticks of veterinary and medical importance.
Despite the virulence and rapid kinetics of challenge infection, DNA vaccination with NP and M achieved limited protection against an H5N1 virus strain isolated from the 1997 human outbreak in Hong Kong (3).
San Diego, CA) announced the issuance of United States Patent 6,586,409, covering DNA vaccination with a novel adjuvant, Vaxfectin.
Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian-human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeys.